Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Completed · Phase 2
Conditions studied: SARS (Severe Acute Respiratory Syndrome), Coronavirus
In brief
Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric oxide is a selective pulmonary vasodilator gas used in as a rescue therapy in refractory hypoxemia due to acute respiratory distress syndrome (ARDS). In-vitro and clinical evidence indicate that inhaled nitric oxide gas (iNO) has also antiviral activity against other strains of coronavirus. The primary aim of this study is to determine whether inhaled NO improves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter single-blinded randomized controlled trial with 1:1 individual allocation
Key facts
- Study ID
- NCT04306393
- Run by
- Massachusetts General Hospital
- People needed
- 200
- Starts
- 2020-03-21
- Expected to finish
- 2022-06-15
- Last updated by the study team
- 2026-04-01
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama — Birmingham, Alabama, United States
- Louisiana State University Health Shreveport — Shreveport, Louisiana, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Danderyd Sjukhus AB — Danderyd, Stockholm County, Sweden
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.